Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod

The safety profile of fingolimod 0.5 mg, approved therapy for relapsing multiple sclerosis, is well established in clinical and real‐world studies. As fingolimod is teratogenic in rats, it was considered important to assess the concentrations of fingolimod and its active metabolite, fingolimod‐phosp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Pharmacol Drug Dev
Hauptverfasser: David, Olivier J., Berwick, Amy, Pezous, Nicole, Lang, Michael, Tiel‐Wilck, Klaus, Ziemssen, Tjalf, Li, Peng, Hara, Hisanori, Schmouder, Robert
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Brief Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814852/
https://ncbi.nlm.nih.gov/pubmed/29266794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.424
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge